These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9777791)

  • 41. Tazarotene.
    Foster RH; Brogden RN; Benfield P
    Drugs; 1998 May; 55(5):705-11; discussion 712. PubMed ID: 9585866
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tazarotene (tazorac) for acne.
    Med Lett Drugs Ther; 2002 Jun; 44(1132):52-3. PubMed ID: 12058150
    [No Abstract]   [Full Text] [Related]  

  • 43. Effect of topical tazarotene in the treatment of congenital ichthyoses.
    Hofmann B; Stege H; Ruzicka T; Lehmann P
    Br J Dermatol; 1999 Oct; 141(4):642-6. PubMed ID: 10583110
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phototoxic and photoallergic potential of tazarotene foam 0.1% in 2 phase 1 patch studies.
    Hogan DJ; Saenz AB
    Cutis; 2012 Nov; 90(5):266-71. PubMed ID: 23270200
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro compatibility of tazarotene with other topical treatments of psoriasis.
    Hecker D; Worsley J; Yueh G; Lebwohl M
    J Am Acad Dermatol; 2000 Jun; 42(6):1008-11. PubMed ID: 10827404
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cumulative irritation potential and contact sensitization potential of tazarotene foam 0.1% in 2 phase 1 patch studies.
    Berg JE; Bowman JP; Saenz AB
    Cutis; 2012 Oct; 90(4):206-11. PubMed ID: 23259209
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Drug interactions in psoriasis: the pros and cons of combining topical psoriasis therapies.
    Endzweig-Gribetz CH; Brady C; Lynde C; Sibbald D; Lebwohl M
    J Cutan Med Surg; 2002; 6(3 Suppl):12-6. PubMed ID: 11976987
    [No Abstract]   [Full Text] [Related]  

  • 48. Early clinical development of tazarotene.
    Marks R
    Br J Dermatol; 1996 Oct; 135 Suppl 49():26-31. PubMed ID: 9035702
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks.
    Weinstein GD; Koo JY; Krueger GG; Lebwohl MG; Lowe NJ; Menter MA; Lew-Kaya DA; Sefton J; Gibson JR; Walker PS;
    J Am Acad Dermatol; 2003 May; 48(5):760-7. PubMed ID: 12734506
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Optimizing treatment with topical tazarotene.
    Guenther LC
    Am J Clin Dermatol; 2003; 4(3):197-202. PubMed ID: 12627995
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial.
    Webster GF; Berson D; Stein LF; Fivenson DP; Tanghetti EA; Ling M
    Cutis; 2001 Jun; 67(6 Suppl):4-9. PubMed ID: 11499329
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Topical tazarotene vs. coal tar in stable plaque psoriasis.
    Kumar U; Kaur I; Dogra S; De D; Kumar B
    Clin Exp Dermatol; 2010 Jul; 35(5):482-6. PubMed ID: 19874376
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tazarotene versus tretinoin or adapalene in the treatment of acne vulgaris.
    Kakita L
    J Am Acad Dermatol; 2000 Aug; 43(2 Pt 3):S51-4. PubMed ID: 10898831
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Histological effects of tazarotene 0.1% cream vs. vehicle on photodamaged skin: a 6-month, multicentre, double-blind, randomized, vehicle-controlled study in patients with photodamaged facial skin.
    Machtinger LA; Kaidbey K; Lim J; Loven KH; Rist TE; Wilson DC; Parizadeh DD; Sefton J; Holland JM; Walker PS
    Br J Dermatol; 2004 Dec; 151(6):1245-52. PubMed ID: 15606521
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combination treatment of psoriasis with photochemotherapy and tazarotene gel, a receptor-selective topical retinoid.
    Behrens S; Grundmann-Kollmann M; Peter RU; Kerscher M
    Br J Dermatol; 1999 Jul; 141(1):177. PubMed ID: 10417841
    [No Abstract]   [Full Text] [Related]  

  • 56. Treatment of psoriasis with retinoids: present status.
    Orfanos CE
    Cutis; 1999 Nov; 64(5):347-53. PubMed ID: 10582161
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Advances in psoriasis therapy.
    Koo J; Nguyen Q; Gambla C
    Adv Dermatol; 1997; 12():47-72; discussion 73. PubMed ID: 8973735
    [No Abstract]   [Full Text] [Related]  

  • 58. [Inhibition of promyelocytic leukemia gene by tazarotene in hyperproliferative epidermis of psoriasis].
    Wang QY; Yan HL; Liu P; Peng ZH; Tan SS
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Aug; 26(8):1146-8. PubMed ID: 16939905
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of treatment of acne vulgaris with alternate-day applications of tazarotene 0.1% gel and once-daily applications of adapalene 0.1% gel: a randomized trial.
    Leyden J; Lowe N; Kakita L; Draelos Z
    Cutis; 2001 Jun; 67(6 Suppl):10-6. PubMed ID: 11499327
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Optimising the use of tazarotene in clinical practice: consensus statement from the European advisory panel for tazarotene (Zorac TM).
    Gollnick HP; Finzi AF; Marks R; Barker JN; Jansen C; Revuz J; Saurat J
    Dermatology; 1999; 199(1):40-6. PubMed ID: 10449956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.